Multiple Myeloma Hub

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye University Ankara Liv Hospital, Ankara, TR. We asked about the key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM. The first analysis explored outcomes among patients who received only one prior LoT, while the second examined outcomes in patients who achieved sustained MRD negativity. This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Binod Dhakal, Medical College of Wisconsin, Milwaukee, US. We asked, What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM? This educational resource is independently supported by Caribou Biosciences. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss strategies for managing belantamab mafodotin-associated ocular toxicities in patients with multiple myeloma (MM). The meeting featured a presentation by guest speaker Lisa Leypoldt, University Medical Center Hamburg-Eppendorf, followed by a faculty discussion on the practical challenges of monitoring, managing, and counseling patients receiving belantamab mafodotin-based therapies. During their presentation, Leypoldt reviewed the mechanisms underlying belantamab mafodotin-associated ocular toxicity, highlighting the role of off-target uptake into corneal epithelial cells and the resulting transient visual symptoms. Leypoldt discussed the clinical manifestations of ocular events, including keratopathy, changes in visual acuity, and patient-reported symptoms, before outlining evidence-based approaches to monitoring and management. Leypoldt also reviewed data from the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) studies, evaluating the role of dose modifications and extended dosing intervals in managing ocular toxicity. The subsequent faculty discussion focused on multidisciplinary care, patient counseling, and practical considerations for integrating ocular toxicity monitoring into routine clinical practice.This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

During the Multiple Myeloma Hub Steering Committee Meeting on May 12, 2026, key opinion leaders met to discuss the integration of B-cell maturation antigen (BCMA)-directed bispecific antibodies (BsAbs) into the treatment paradigm for multiple myeloma. The discussion was led by Miles Prince (Peter MacCallum Cancer Centre, Melbourne, AU) and explored key considerations for patient selection, treatment sequencing, and implementation of BsAb therapy in clinical practice. Prince reviews the currently approved BCMA-directed BsAbs and key factors influencing treatment selection, including disease burden, prior therapy, T-cell fitness, patient preferences, and treatment access. Prince also discusses emerging treatment strategies, including combination regimens and earlier-line use of BsAbs, before exploring practical considerations related to dosing, toxicity management, and community-based treatment delivery. The subsequent discussion focuses on expanding access to BsAb therapy, the role of standardized toxicity management pathways, and challenges associated with transitioning patients from specialist centers to community care. This educational resource is independently supported by Pfizer. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.

During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM? This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What’s on the horizon for the treatment of relapsed/refractory multiple myeloma (MM) in 2026? In this interview, Lonial provides an overview of recent and emerging developments in relapsed/refractory MM, highlighting advances in immune-based therapies and their potential to improve outcomes in the early relapsed setting. He also discusses how these approaches may influence treatment decision-making, the movement of novel therapies into earlier lines of treatment, and the broader implications for future disease management.